Down-regulation of the Sodium/Iodide Symporter Explains 131I-Induced Thyroid Stunning
Open Access
- 1 August 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (15), 7512-7517
- https://doi.org/10.1158/0008-5472.can-07-0823
Abstract
131I radiation therapy of differentiated thyroid cancer may be compromised by thyroid stunning (i.e., a paradoxical inhibition of radioiodine uptake caused by radiation from a pretherapeutic diagnostic examination). The stunning mechanism is yet uncharacterized at the molecular level. We therefore investigated whether the expression of the sodium/iodide symporter (NIS) gene is changed by irradiation using 131I. Confluent porcine thyroid cells on filter were stimulated with thyroid-stimulating hormone (TSH; 1 milliunit/mL) or insulin-like growth factor-I (IGF-I; 10 ng/mL) and simultaneously exposed to 131I in the culture medium for 48 h, porcine NIS mRNA was quantified by real-time reverse transcription-PCR using 18S as reference, and transepithelial iodide transport was monitored using 125I− as tracer. TSH increased the NIS expression >100-fold after 48 h and 5- to 20-fold after prolonged stimulation. IGF-I enhanced the NIS transcription at most 15-fold but not until 5 to 7 days. 131I irradiation (7.5 Gy) decreased both TSH-stimulated and IGF-I–stimulated NIS transcription by 60% to 90% at all investigated time points. TSH and IGF-I stimulated NIS synergistically 15- to 60-fold after 5 days. NIS expression was reduced by 131I also in costimulated cells, but the transcription level remained higher than in nonirradiated cells stimulated with TSH alone. Changes in NIS mRNA always correlated with altered 125I− transport in cultures with corresponding treatments. It is concluded that down-regulation of NIS is the likely explanation of 131I-induced thyroid stunning. Enhanced NIS expression by synergistically acting agents (TSH and IGF-I) partly prevents the loss of iodide transport expected from a given absorbed dose, suggesting that thyroid stunning might be pharmacologically treatable. [Cancer Res 2007;67(15):7512–17]Keywords
This publication has 41 references indexed in Scilit:
- A perspective view of sodium iodide symporter research and its clinical implicationsActa Endocrinologica, 2006
- Chromatin in Need of a Fix: Phosphorylation of H2AX Connects Chromatin to DNA RepairMolecular Cell, 2005
- Whole-body scanning with radionuclides of iodine, and the controversy of ???thyroid stunning???Nuclear Medicine Communications, 2004
- The Functional Interaction between the Paired Domain Transcription Factor Pax8 and Smad3 Is Involved in Transforming Growth Factor-β Repression of the Sodium/Iodide Symporter GeneJournal of Biological Chemistry, 2004
- Thyroid StunningThyroid®, 2003
- Relative expression software tool (REST(C)) for group-wise comparison and statistical analysis of relative expression results in real-time PCRNucleic Acids Research, 2002
- PI3K Is Involved in the IGF-I Inhibition of TSH-Induced Sodium/Iodide Symporter Gene ExpressionMolecular Endocrinology, 2002
- A new mathematical model for relative quantification in real-time RT-PCRNucleic Acids Research, 2001
- Escape from the Acute Wolff-Chaikoff Effect Is Associated with a Decrease in Thyroid Sodium/Iodide Symporter Messenger Ribonucleic Acid and ProteinEndocrinology, 1999
- Insulin and insulin-like growth factor I regulate a thyroid-specific nuclear protein that binds to the thyroglobulin promoterMolecular Endocrinology, 1992